Immunotherapy is a promising approach for the treatment of cancers. Modified adenovirus 5 (Ad5) vectors have been used as a platform to deliver genes encoding tumor associated antigens (TAA). A major obstacle to Ad5 vector immunotherapy has been the induction of vector immunity following administration or the presence of pre-existing Ad5 immunity, which results in vector mitigation. It has been reported by us that the Ad5[E1-, E2b-] platform with unique deletions in the E1, E2b and E3 regions can induce potent cell mediated immunity (CMI) against delivered transgene products in the presence of pre-existing Ad5 immunity. Here we report the use of an Ad5[E1-, E2b-] vector platform expressing the TAA HER2/neu as a breast cancer immunotherapeutic agent. Ad5[E1-, E2b-]-HER2/neu induced potent CMI against HER2/neu in Ad5 naïve and Ad5 immune mice. Humoral responses were also induced and antibodies could lyse HER2/neu expressing tumor cells in the presence of complement in vitro. Ad5[E1-, E2b-]-HER2/neu prevented establishment of HER2/neu-expressing tumors and significantly inhibited progression of established tumors in Ad5 naïve and Ad5 immune murine models. These data demonstrate that in vivo delivery of Ad5[E1-, E2b-]-HER2/neu can induce anti-TAA immunity and inhibit progression of HER2/neu expressing cancers.
Introduction
Tumor associated antigens (TAA) are typically weak immunogens; however, anti-tumor effects in many immunotherapeutic studies have been correlated with the induction of T-cell responses against TAA. Therapeutic administration of a patient's autologous dendritic cells (DC) extracorporeally loaded with a TAA has exhibited survival benefit. 1 Non-viral and viral vector platforms encoding TAA epitopes have been investigated as therapeutic vaccines. 2 Importantly, viral vectors effectively transfect DC leading to antigen processing and immune presentation. [3] [4] [5] Of the viral vectors investigated, adenovirus 5 (Ad5) has been reported to induce robust T-cell and antibody responses against the delivered transgene product. 6, 7 DC infection with Ad5 vectors encoding a variety of antigens, including the tumor antigens MART-1, MAGE-A4, DF3/MUC1, p53, hugp100 melanoma antigen and polyoma virus middle-T antigen, have been reported to induce antigen specific cytotoxic T lymphocyte responses, have an enhanced antigen presentation capacity, and initiate T-cell proliferation in mixed lymphocyte reactions. [8] [9] [10] [11] [12] Arthur et al. demonstrated that Ad5 vectors encoding a variety of antigens could efficiently transduce 95% of in vivo exposed DCs to high titers of the vector. 13 Increasing levels of foreign gene expression were noted in DC during increasing multiplicities of infection. 10 Ad5 infection has been reported to result in direct induction of DC maturation 14, 15 and triggers interleukin (IL) 12 production by DC, which is a marker of DC maturation. 15 These events may possibly be the result of nuclear factor kB pathway interaction due to Ad5 viral infection. [15] [16] [17] Immunization of animals with DC that have been previously transduced with Ad5 vectors encoding TAA has been reported to result in significant levels of protection when animals were challenged with tumor cells expressing the immunizing TAA. 18 Studies of immature bone marrow-derived DC from mice suggest that Ad5 vector infection can result in upregulation of cell surface markers, MHC I and II, CD40, CD80, CD86 and ICAM-1, normally associated with DC maturation as well as downregulation of CD11c, an integrin known to be downregulated upon myeloid DC maturation.
The major limitation of immunotherapy using Ad5 vectored TAA is rapid neutralization of the vector due to host anti-vector immunity. The preponderance of humans harbor Ad5 immunity due to natural infection and this immunity has been reported to be a barrier to immunization in multiple animal models and in human clinical trials. [19] [20] [21] [22] [23] The use of different Ad serotypes or even non-human forms of Ad have been evaluated in an effort to overcome pre-existing Ad5 immunity. 19 Another strategy to overcome Ad5 immunity is to delete Ad5 genes necessary for producing viral proteins against which naturally arising cell mediated immunity (CMI) and antibodies react. Current recombinant Ad5 vectors are deleted in the E1/E3 regions (Ad5[E1-]). We and others have reported on immunization protocols using an improved Ad5 vector deleted in the early 1 (E1), early 2b (E2b) and early 3 (E3) gene regions (Ad5[E1-, E2b-]). 22, [24] [25] [26] [27] The deletion of the Ad5 polymerase and preterminal protein within the E2b region has been reported to reduce Ad5 downstream gene expression, which includes Ad5 late genes that encode highly immunogenic and potentially toxic proteins. 24, 28 As a result, in vivo use of the Ad5[E1-, E2b-] vector platform has been reported to extend transgene expression, reduce inflammatory responses and exhibit fewer hepatic adverse effects. 26, 28 This novel vector platform has also been reported to induce potent CMI responses in the presence of Ad5 immunity. 22, 27, 29 We recently reported on the use of the Ad5[E1-, 29 Here we investigated the use of an Ad5[E1-, E2b-] platform expressing the TAA HER2/neu to induce immune responses in an animal model. HER2/neu protein expression has been indentified in up to 10-34% of invasive breast cancers and is associated with aggressive tumor progression, shorter relapse time following treatment and reduced survival. 30, 31 The immunogenicity of HER2/neu has been well demonstrated in phase I and phase II clinical trials. 32, 33 In one study, 31 patients with stage III or IV HER2/neu positive breast cancer received monthly immunization with a HER2/neu-derived T helper epitope administered with granulocyte colony stimulating factor for 6 months. 32 Following the treatments, 92% of patients demonstrated HER2/neu immunity as measured by T-cell proliferation and this immunity lasted for at least 1 year in 38% of responding patients. 32 In another vaccine trial, patients were administered an immunogenic peptide from the HER2/neu protein (E75) in combination with granulocyte colony stimulating factor to prevent recurrence in resected node-positive and nodenegative breast cancer patients. 33 After vaccination all patients demonstrated delayed type hypersensitivity response and immunologic responses in an in vitro assay. A recurrence rate of 5.6% was reported in immunized patients compared with 14.2% in the controls (P ¼ 0.04) at a median of 20 months follow-up. 33 The demonstrated immunogenicity, high expression and association with poor prognosis makes HER2/neu a promising target for CMI induced immunotherapy or prophylactic vaccination. To test the hypotheses that Ad5[E1-, E2b-] vectored TAA can induce immunity in the Ad5 host immune state; we investigated the potential of the Ad5[E1-, E2b-]-HER2/neu vector to induce CMI and antibody responses in Ad5 naı¨ve and Ad5 immune mice. Furthermore, we evaluated the propensity of the Ad5[E1-, E2b-]-HER2/ neu vector to inhibit the progression of HER2/neu expressing tumors in vivo.
Materials and methods

Animals
Specific pathogen-free, BALB/c mice (Charles River, Wilmington, MA) ages 6-8 weeks old were housed in animal facilities at the Infectious Disease Research Institute (IDRI) (Seattle, WA). All procedures were conducted according to Institutional Animal Care and Usage Committee (IACUC) approved protocols. All mice were availed food and water ad libitum. In Ad5 immunized studies, mice were made Ad5 immune by immunizing Ad5 naı¨ve BALB/c mice twice at a 2-week interval with 10 10 VP of Ad5[E1-]-null (no transgene). This protocol has been reported by us to induce Ad5 neutralizing antibody (NAb) and CMI against Ad5. 22, 34 The presence of pre-existing Ad5 immunity in Ad5[E1-]-null immunized mice was confirmed using an Ad5 NAb assay (see section Adenovirus neutralization assay).
Vector platforms
Ad5[E1-, E2b-]-HER2/neu was constructed and produced as previously described 22 using a human modified HER2/ neu as the insert, kindly provided by Dr Timothy Clay, Duke University. 35 Briefly, the HER2/neu complementary DNA was sub-cloned into the E1 region of the Ad5[E1-, E2b-] vector using a previously described homologous recombination based procedure. 24, 25 HER2/neu production was placed under the control of a cytomegalovirus enhancer/promoter element. The replication deficient virus was then propagated in the necessary and sufficient E.C7 packaging cell line, CsCl 2 purified, dialyzed and then titered as previously described. 22, 24 The plaque forming units (PFU) and virus particle (VP) numbers of Ad5[E1-, E2b-]-HER2/neu were determined. The infectious titer as determined on an E.C7 cell monolayer was 1.0 Â 10 10 PFU per ml. The VP concentration was determined by SDS disruption and spectrophotometry at 260 and 280 nm and was 0. 22 Briefly, 10 6 human lung carcinoma cells (A-549) (ATCC number CCL-185) were infected at a multiplicity of infection of 100 VP per cell, incubated for 24 h, followed by lysis of the cells. A-549 cell lysates were separated on a 10% SDS-polyacrylamide gel and transferred onto a polyvinylidene fluoride membrane (GE Healthcare, Piscataway, NJ). The membrane was then blocked with Tris-buffered saline containing 5% (w/v) blocking reagent for 2 h at room temperature and sequentially incubated with mouse HER2/neu antibody (1:250) (Genway, San Diego, CA) and goat anti-mouse horseradish peroxidase conjugated antibody (1:1000) (Kirkegaard and Perry Laboratories, Gaithersburg, MD) for 1 hour at room temperature. Reactivity was determined by chemilluminescence using an ECL western blotting analysis system (GE Healthcare) according to the manufacturer's specifications.
Adenovirus neutralization assay
Dilutions of heat-inactivated mouse sera in 100 ml Dulbecco's modified Eagle medium containing 10% fetal calf serum were mixed with 4 Â 10 7 VP Ad5[E1-]-null and incubated for 60 min. The samples were then added to microwells of a 96-well plate containing HEK-293 cells at 2 Â 10 3 cells per well and incubated for 72 h. An MTS bioreduction assay was used to quantify cell death, and endpoint Ad5 NAb titers were determined. 22 Enzyme linked immunosorbent assay for HER2/neu antibody Mouse sera were collected and frozen at À20 1C until assayed. Microtiter plates for enzyme linked immunosorbent assay (Nunc, Rochester, NY) were coated with 150 ng of purified HER2/neu protein (GenWay). Plates were incubated at room temperature overnight, washed with phosphate-buffered saline and blocked with 1% bovine serum albumin in phosphate-buffered saline for 30 min. Thawed sera were diluted 1:100 with 1% bovine serum albumin in phosphate-buffered saline and 200 ml was added to each well. Samples were incubated for 1 h followed by incubation with 200 ml of a 1:12 500 dilution of goat peroxidase-conjugated anti-mouse immunoglobulin (Ig) G (g-chain specific) (Sigma Chemicals, St Louis, MO) for 1 h at room temperature. The 96-well plates were washed three times and 200 ml per well of 1,2-phenylenediamine substrate solution was added to each well. The reaction was stopped by adding 50 ml per well of a 5N HCl solution. Absorbance was measured at 492 nm. A standard IgG reference curve was concomitantly generated using purified mouse IgG (Sigma Chemicals). The optical density reading of unknown samples were correlated against the standard IgG curve to obtain nanogram equivalents of IgG bound per well utilizing an INSTAT statistical program as previously described. 37 In vitro tumor binding antibody assay CT26-HER2/neu tumor cells were harvested by physical scraping from T75 flasks (Corning, Corning, NY) then washed three times with phosphate-buffered saline þ 5% fetal calf serum. Cells stained with mouse sera were left intact. Cells stained with a commercial antibody were first permeabilized by a 30 min incubation with 1X BD perm/ wash (Becton Dickinson, Franklin Lakes, NJ) to allow for detection of antibody directed at the intracellular region of HER2/neu and all subsequent procedures for these cells were performed using this buffer. Permeabilized cells were incubated with 0.25 mg ml Complement-dependent cellular cytotoxicity assay CT26-HER2/neu tumor cells were cultured overnight at a density of 2 Â 10 4 cells per well in 96-well tissue culture microplates. Pooled mouse sera was added at a 1:100 dilution and incubated at 37 1C for 1 hour. Rabbit serum was then added at a 1:100 dilution as a source of complement and cells were incubated an additional 2.5 h at 37 1C. For control studies, rabbit serum was heat inactivated by incubation for 1 h at 56 1C before use. Cell culture supernatants were assayed using Promega cytotox 96 non-radioactive cytotoxicity assay (Promega, Madison, WI), according to the manufacturer's instructions. Percent lysis of CT26-HER2/neu cells was calculated by the formula:
Enzyme-linked immunosorbent spot (ELISpot assay) ELISpot assays were used to determine the number of HER2/neu-specific interferon-g (IFN-g) or IL-2 secreting T-cells from freshly collected mouse splenocytes as previously described. 22 The ELISpot assay was run according to the manufacturer's specifications (eBioscience, San Diego, CA). Briefly, 2 Â 10 5 mouse splenocytes were seeded per well in a 96-well microtiter plate and cytokine secreting T cells were reported as the number of spots per 10 6 spleocytes. HER2/neu peptides (kindly provided by Dr Timothy Clay, Duke University), b-galactosidase protein (Rockland, Gilbertsville, PA), cytomegalovirus pp65 (495-503) peptides (Beckman Coulter, San Diego, CA) and HIV-1 Gag (p24) protein (IDRI) were used as stimulants at a final concentration of 1 mg per well for protein and 0.1 mg per well for peptides. Cells stimulated with concanavalin A at a concentration of 0.0625 mg per well served as a positive control. Colored spot-forming cells were counted using an Immunospot ELISpot plate reader (Cellular Technology, Shaker Heights, OH) and responses were considered to be positive if, (1) X50 spot-forming cells/10 6 cells were detected after subtraction of the number of spots in the negative control wells and (2) spot-forming cells were X2-fold greater than those detected in the negative control wells. 2 /2 as previously described. 29, 38 Tumor studies were terminated when a pre-determined IACUC defined maximum tumor size was achieved in mice.
Prevention of tumor establishment
Tumor treatment studies To determine if a reduction of tumor progression could be achieved in established HER2/neu expressing tumors, mice were implanted with 10 6 CT-26-HER2/neu cells SQ in the left subcostal region on day 0. Once tumors were palpable, mice were treated by administration of injection buffer, 10 10 VP of Ad5[E1-, E2b-]-null or 10 10 VP of Ad5[E1-, E2b-]-HER2/neu in the right flank on days 7 and 14. Tumor growth was determined, volumes were calculated and studies were terminated as described in the previous section.
Statistical analysis
Statistical analysis was performed using GraphPad Prism. Statistically significant differences were determined by comparative Student's t-tests with a P-value of p0.05 being considered significant.
Results
Characterization of Ad5 HER2/neu vector As determined by plaque assay and spectrophotometry, the ratio of Ad5[E1-, E2b-]-HER2/neu VP to PFU was . Fourteen days after the final immunization, splenocytes from the mice were assessed by ELISpot analysis. The greatest induction of CMI was achieved using 10 10 VP of the vector. For positive controls, splenocytes were exposed to concanavalin A in all ELISpot assays as described (data not shown). The error bars depict the standard error of the mean (s.e.m.).
Immune activation using
weeks following the last immunization, splenocytes were exposed to HER2/neu peptides or irrelevant antigens and analyzed by ELISpot for the number of IFN-g and IL-2 secreting T cells. As shown in Figure 2a , significantly elevated numbers of IFN-g and IL-2 secreting cells were observed in Ad5 naı¨ve mice after one, two or three immunizations with Ad5[E1-, E2b-]-HER2/neu. The numbers of IFN-g and IL-2 secreting cells observed after two or three immunizations were significantly higher than those observed after one immunization (Po0.02 and Po0.002, respectively). However, the differences were not statistically significant between two and three immunizations. Specificity studies revealed that CMI responses were specific to HER2/neu and there were no responses against irrelevant antigens such as the cytomegalovirus antigen, b-galactosidase or HIV-1 Gag (data not shown).
Experiments were performed to assess immune responses in Ad5 immune mice following a single or multiple immunizations. To induce Ad5 immunity, Ad5 naı¨ve BALB/c mice (n ¼ 5/group) were injected SQ twice at 2-week intervals with 10 10 VP of Ad5-null. Two weeks following the final Ad5-null administration, serum samples were collected and assessed for endpoint neutralizing Ad5 antibody titers. Assessment of sera 2 weeks after the final Ad5-null immunization revealed that the average endpoint Ad5 NAb was 1:100. Mice were then immunized once, twice, or three times at weekly intervals with 10 10 VP of Ad5[E1-, E2b-]-HER2/neu. Two weeks following the final immunization, splenocytes were assessed for the number of IFN-g and IL-2 secreting cells by ELISpot analysis. Vaccine induced HER2/neu specific IFN-g and IL-2 secretion was significantly reduced in the Ad5 immune mice as compared with the Ad5 naı¨ve mice. Again, as observed in the Ad5 naı¨ve mice above, the highest average numbers of IFN-g and IL-2 secreting splenocytes in Ad5 immune mice were obtained 2 weeks after a third immunization (Figure 2b ). IFN-g secretion increased significantly (Po0.005) after two and three vaccine administrations but not after one. Significant increases (Po0.03) in IL-2 secretion over control values were also noted after each immunization. Although significantly higher than control values, the increases in IL-2 secretion between one and two immunizations were not significantly different from each other (P ¼ 0.0504). The levels of IL-2 secretion observed after the third immunization were significantly elevated as compared with the levels observed after one or two immunizations (Po0.0001 and P ¼ 0.0073, respectively). Sera collected from mice after the final immunization revealed that the average endpoint Ad5 NAb titer was 1:500, indicating hyper immune levels to Ad5. These results demonstrate that immunization(s) of Ad5 naı¨ve or Ad5 immune mice with Ad5[E1-, E2b-]-HER2/neu induced HER2/neu-specific CMI responses with the highest responses occurring 2 weeks after three immunizations. This study was then repeated in Ad5 immune mice (n ¼ 7/group). These mice were made Ad5 immune by two immunizations with Ad5[E1-]-null at a 2-week interval. Two weeks later, the mice were immunized three times at weekly intervals with Ad5[E1-, E2b-]-HER2/neu. Two weeks following the final immunization, mice were inoculated with 10 6 CT-26-HER2/neu cells in the right subcostal region. As was observed in Ad5 naı¨ve mice, Ad5 immune mice had significant reduction of tumor progression on day 9 (Po0.01), 11 (Po0.001) 14 (Po0.001) and 18 (Po0.001) as compared with Ad5[E1-, E2b-]-null injected and control groups (Figure 4b ).
Induction of humoral immune responses by Ad5[E1-, E2b-]-HER2/neu
Treatment of established HER2/neu expressing tumors
The effectiveness of treating established HER2/neuexpressing CT-26-HER2/neu tumors in vivo with Ad5[E1-, E2b-]-HER2/neu was evaluated. Ad5 naı¨ve or Ad5 immune BALB/c mice (n ¼ 7/group) were implanted SQ into the right subcostal with 10 6 CT-26-HER2/neu cells on day 0. Tumors were palpable by days 4-6. On days 7 and 14, mice were treated by SQ injections of injection buffer alone, 10 10 VP of Ad5[E1-, E2b-]-null or 10 10 VP of Ad5[E1-, E2b-]-HER2/neu. All mice were monitored for tumor growth and tumor volumes were calculated. Ad5 naı¨ve mice immunized with Ad5[E1-, E2b-]-HER2/neu had significantly smaller tumors than control mice on days 11, 14 and 16 (Po0.05) (Figure 5a ). Of particular importance is the observation that Ad5 immune mice treated with Ad5[E1-, E2b-]-HER2/neu had significantly smaller tumors than control mice measured on days 11, 14 and 16 (Po0.05) (Figure 5b ). These results demonstrate that the Ad5[E1-, E2b-]-HER2/neu vector platform has the potential to be utilized as an immu- notherapeutic agent to treat HER2/neu expressing tumors in a clinically relevant Ad5 immune setting.
Discussion
In the present study, we report that dose dependent immune responses against the TAA HER2/neu were induced by Ad5[E1-, E2b-]-HER2 in Ad5 naı¨ve and Ad5 immune mouse models. These responses were demonstrated by increases in the levels of IFN-g and IL-2 secreting splenocytes and HER2/neu antibody induction after immunization(s). The CMI and antibody responses induced by vaccination trended to be the most robust 2 weeks after three immunizations as compared with 2 weeks after one or two immunizations. We have yet to determine if the highest levels of CMI and antibody responses observed in mice receiving three immunizations was the result of multiple administrations or was due to the longer vaccination time in mice that received three dosages as compared with the shorter vaccination times after one or two doses. (Figure 1 ). Osada, et al. used an immunizing dose more than two times higher than the dose used in the current study (2.6 Â 10 10 verses 1.0 Â 10 10 VP, respectively), which may have contributed to the contrast in immune induction results. 27 Also, the ratio of PFU to VP of the Ad5[E1-, E2b-]-HER2/neu used in the current study was 1:90 (PFU/VP), which is high for Ad5 preparations that ideally have a ratio of 1:30 or less as stipulated by the Food and Drug Administration for Ad5-based vectors. We expect that optimization of manufacturing conditions will improve this ratio, which, in turn, may improve the vaccine efficiency of this new vector platform resulting in greater immune responses. Even though reductions in HER2/neu specific responses occurred in Ad5 immune mice and the PFU/VP ratio of the Ad5[E1-, E2b-]-HER2 viral prep was high relative to other studies, the levels of induced immune responses resulted in significant therapeutic and prophylactic benefit in tumor treatment and tumor challenge studies. Thus, the influence of Ad5 immunity on induced immune responses is apparent, yet, despite this influence, the improved Ad5[E1-, E2b-] vector platform can still induce anti-tumor immunity.
In order to induce effective anti-tumor immunity, vectored immunotherapeutic cancer agents targeting TAA must be potent even in the presence of anti-vector immunity, independent of whether pre-existing vector immunity has been established though natural infection or newly acquired immunity is developed following primary immunizations using vectored vaccines. Studies in humans and animals using Ad5 vectors, the most widely used subtype for human vector vaccines, have demonstrated that pre-existing Ad5 immunity can mitigate immunization, especially re-immunization. This Ad5 immunity may preclude the repeated administration of current generation Ad5[E1-]-based vaccines. 19, 22, 23 A preponderance of humans has neutralizing antibodies to Ad5, with two-thirds of humans studied having lymphoproliferative responses against Ad5. 21 Overcoming the barrier of pre-existing Ad5 anti-vector immunity has been a subject of intense investigation. The use of different Ad serotypes or even non-human forms of Ad have been evaluated in efforts to overcome pre-existing Ad5 immunity. 19 Even if these approaches succeed in an initial immunization, subsequent vaccination using that serotype would be mitigated due to the immune response induced against that subtype. These observations, coupled with the altered biodistribution and potentially increased toxicity of alternative serotype vectors along with serotype cross-reactivity renders these diverse approaches problematic, especially relative to the well-characterized Ad5[E1-] platform. 39 In order to retain the positive attributes of Ad5 vectors while moving toward overcoming such limitations, next generation Ad5 vectors have been constructed using further deletion of Ad5 viral genes. Our Ad5[E1-, E2b-] platform has additional deletions in the Ad5 DNA polymerase and the preterminal protein genes that are contained in the E2b genome region. As a result, it has an expanded cloning capacity with up to a 12 kb gene-carrying capacity as compared with the 7 kb capacity of 40 Deletion in the early gene 2b (E2b) region has been reported to allow for induction of potent immune responses to transgene specific antigens in the presence of Ad5 immunity. We previously reported on the development of an Ad5[E1-, E2b-]-HIV-1 vector vaccine that generated significantly higher CMI responses following multiple immunizations as compared with the current generation Ad5[E1-]-HIV-1 vector. 22, 34 Moreover, significant antigen specific CMI responses were induced in mice and non-human primates despite the presence of pre-existing Ad5 immunity. 22, 34 In addition, we have recently extended studies of Osada et al. 27 and have demonstrated that immunotherapy of Ad5 immune mice with Ad5[E1-, E2b-]-CEA can significantly decrease progression of CEA expressing tumors in comparison with a current generation Ad5[E1-]-CEA. 29 Supporting evidence for the present study has also been put forth by Hartman et al., 35 employing a current generation Ad5[E1-]-HER2/neu vector in a HER2/neu tolerant transgenic mouse model. They reported that immunization with the vector platform induced HER2/neu specific immune responses in Ad5 naı¨ve HER2/neu transgenic mice. 35 Additionally, immunotherapy of HER2/neu expressing tumors in their tolerant transgenic model resulted in significant inhibition of tumor progression. Thus, not only could an Ad5-HER2/neu vector break tolerance in transgenic mice, it could induce robust immune responses resulting in anti-tumor activity. The above findings and the observations in the present study have important implications in the immunotherapy of Ad5 immune HER2/neu positive cancer patients with the Ad5[E1-, E2b-]-HER2/neu vector.
The results of the studies employing Ad5[E1-, E2b-]-CEA and Ad5[E1-, E2b-]-HER2/neu collectively demonstrate the immunotherapeutic potential of this new vector platform approach for the treatment of certain cancers. Of particular importance is the observation that the Ad5[E1-, E2b-] vector can induce immune responses resulting in significant anti-tumor responses in a clinically relevant Ad5 immune setting. Given the results reported herein, we believe that Ad5[E1-, E2b-]-HER2/neu warrants further investigation and clinical trial testing in patients with HER2/neu expressing cancers. In addition, further studies need to be performed to elucidate the mechanism of action that induces the anti-TAA responses in both Ad5 naı¨ve and Ad5 immune hosts. The levels and breath of the CMI responses needs clarification as well as the implications of the TAA antibody responses with respect to tumor cell killing and inhibition of progression.
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